A patient who has read about ketamine therapy has three obvious options: book with the clinic they found, ask a psychiatrist, or wait for the next visit with you and ask then.
Most choose the third. The reasons shape how the question arrives and what the patient needs from your answer.
The evidence comes from our commissioned survey of 443 adults, 18 to 64, in Missouri and nine neighboring states, which looked at how people decide about ketamine and esketamine treatment. The numbers are final.
The magnitude first
A recommendation from their own physician is what would make 74 percent of respondents try this treatment. An ad would do it for 2 percent, a podcast host for 1, a friend or family member for 18, and someone with a service or first responder background they follow online for 4.
As a first stop, respondents chose primary care (56 percent) over psychiatry or another mental health clinician (23 percent), with independent searching at 12, asking a friend at 1, and 5 percent unsure entirely.
Why primary care and not psychiatry
Three things seem to do the work, none of them a judgment about specialty expertise.
Access comes first. A patient with an established primary care relationship already has a route, while new psychiatry appointments often do not exist on a comparable timeline, especially outside metropolitan Missouri.
Second is the chart. Patients sense that the answer depends on what they have already taken, and the office holding that record feels like the right place to ask, which is clinically sound.
Third is legitimacy. This category carries a cultural association older than its clinical use, and patients want the idea validated by someone whose judgment they already rely on. A trusted generalist saying "this is a real treatment, and here is who handles it" settles a doubt no amount of reading settles.
Why the question will not sound like a question about treatment
Patients cannot ask for what they cannot name, and the naming problem is severe. Among respondents, 73 percent had never heard the word Spravato, 21 percent knew the name without content, and 6 percent knew what it was.
Our open-ended question about search terms drew 319 answers, and the vocabulary was symptomatic, not pharmacologic: "help with ptsd," "therapist near me," "how to overcome depression," "depression medicine alternatives."
So the 74 percent finding will rarely present as a request. It shows up as fatigue, as a report that the current medication is not doing much, or as a partner saying the patient has not been themselves. Whether the conversation about newer options happens depends largely on whether you open it.
What the patient is silently evaluating
Legitimacy is explicit. FDA approval settled the matter for 19 percent of respondents and weighed heavily for 40 percent (59 percent combined); 27 percent called it somewhat important and 14 percent indifferent. Telling a patient the treatment carries FDA approval for treatment-resistant depression materially changes willingness, so say it rather than assume it is understood.
Cost weighs more. Coverage ranked first or second for 85 percent, beating proximity at 43, FDA approval at 27, speed at 24, discretion at 11, and a first responder or veteran focus at 10. Insurance could all but decide treatment for 65 percent, and half preferred a covered path with more friction to faster self-pay, the remainder splitting between paying and uncertainty.
Logistics matter more than the telehealth conversation suggests. In-person clinic care was the preference of 44 percent, home telehealth of 22 percent, a clinic-first then home arrangement of 23 percent, and 11 percent had none. When treatment means supervised dosing, a wait, and someone to drive, distance is real and, across Missouri, sometimes decisive.
Who is in the room
The sample's makeup is worth keeping in mind. Most respondents, 58 percent, chose none of the listed descriptors, but 29 percent were relatives of a veteran or first responder, 6 percent married to or partnered with one, 4 percent first responders by trade, and 2 percent veterans or active-duty service members; about 7 percent were veterans or first responders themselves. TRICARE appeared in the payer mix at 5 percent, alongside commercial plans (39), Medicaid (37), Medicare (23), and no insurance (9), with multiple selections allowed.
The distinction patients will not draw for themselves
Esketamine, marketed as Spravato, carries FDA approval specifically for treatment-resistant depression, with dosing supervised in certified settings and monitored afterward. Ketamine prescribed off label, by infusion or shipped home by a direct-to-consumer service, is a separate matter with separate oversight. Patients use one word for all of it, and since the brand name was news to 73 percent of respondents, they cannot tell these apart alone. Brain Recovery Centers' overview of its Spravato care is one patient-facing page that can reinforce the distinction after the visit.
What follows for a Missouri practice
- Treat a report of inadequate response as a cue to review the adequacy of prior trials, dose and duration included, and record the result in a form a prior authorization can use.
- Say which treatment you mean and whether it carries FDA approval for the indication; that one sentence addresses what 59 percent of respondents called deciding or big for them.
- Know the coverage posture of the certified sites you refer to, Medicaid participation included, before naming one.
- Ask about transportation and time for observation before assuming an in-person site is workable.
- Declining without a next step often routes the patient to an unguided search, where the least regulated options are most visible.
This describes patient decision behavior, not clinical guidance, and recommends neither for nor against any therapy; suitability belongs to the treating clinician.
Finally, a line for any reader. When depression turns into thoughts of suicide, the right response is immediate, not scheduled: call or text 988, free, from anywhere in the country, any hour of any day. Encourage people to use it, and use it yourself if that is where you are.
Methodology
This site's publisher both commissioned the study and paid its costs. Pollfish fielded it on its consumer panel, gathering responses by June 23, 2026 from the general population, not a patient registry: 443 people aged 18 through 64 spread among ten Midwest states, all of whom passed a consent screener. Self-reported experience items are not diagnostic. Multi-answer questions are proportions of respondents and sum past 100. All values reflect the panel's finished validation.